humanizované monoklonální protilátky [Antibodies, Monoclonal, Humanized]

tematický
2 757
Termíny

humánní monoklonální protilátky
monoklonální protilátky humanizované

 

Antibodies, Humanized

Perzistentní odkaz   https://www.medvik.cz/link/D061067
Definice

Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.

DUI
D061067 MeSH Prohlížeč
CUI
M0556300
Předchozí užití
Antibodies, Monoclonal (1991-2011)
Historická pozn.
2012
Veřejná pozn.
2012

D Chemikálie a léčiva
D12.776 proteiny 2 575
D12.776.124 krevní proteiny 909
D12.776.124.486 imunoproteiny 14
D12.776.124.486.485 imunoglobuliny 1 483
D12.776.124.486.485.114 protilátky 1 814
D12.776.124.486.485.114.224 monoklonální protilátky 4 611
D12.776.124.486.485.114.224.060 humanizované monoklonální protilátky 2 757
D12.776.124.486.485.114.224.060.125 abciximab 14
D12.776.124.486.485.114.224.060.250 adalimumab 346
D12.776.124.486.485.114.224.060.313 alemtuzumab 123
D12.776.124.486.485.114.224.060.344 basiliximab 2
D12.776.124.486.485.114.224.060.375 bevacizumab 444
D12.776.124.486.485.114.224.060.438 brentuximab vedotin 38
D12.776.124.486.485.114.224.060.500 certolizumab pegol 47
D12.776.124.486.485.114.224.060.750 cetuximab 185
D12.776.124.486.485.114.224.060.766 daklizumab 6
D12.776.124.486.485.114.224.060.782 denosumab 150
D12.776.124.486.485.114.224.060.790 gemtuzumab 16
D12.776.124.486.485.114.224.060.794 inotuzumab ozogamicin 11
D12.776.124.486.485.114.224.060.798 ipilimumab 251
D12.776.124.486.485.114.224.060.813 natalizumab 156
D12.776.124.486.485.114.224.060.829 nivolumab 425
D12.776.124.486.485.114.224.060.844 omalizumab 111
D12.776.124.486.485.114.224.060.860 palivizumab 12
D12.776.124.486.485.114.224.060.864 panitumumab 57
D12.776.124.486.485.114.224.060.866 ramucirumab 1
D12.776.124.486.485.114.224.060.868 ranibizumab 60
D12.776.124.486.485.114.224.060.875 trastuzumab 267
D12.776.124.486.485.114.224.060.937 ustekinumab 120
D12.776.124.486.485.114.224.075 myší monoklonální protilátky 146
D12.776.124.486.485.114.224.342 kombinovaná protilátková terapie 7
D12.776.124.486.485.114.224.608 infliximab 340
D12.776.124.486.485.114.224.785 jednořetězcové protilátky 7
D12.776.124.790 sérové globuliny 61
D12.776.124.790.651 imunoglobuliny 1 483
D12.776.124.790.651.114 protilátky 1 814
D12.776.124.790.651.114.224 monoklonální protilátky 4 611
D12.776.124.790.651.114.224.060 humanizované monoklonální protilátky 2 757
D12.776.124.790.651.114.224.060.125 abciximab 14
D12.776.124.790.651.114.224.060.250 adalimumab 346
D12.776.124.790.651.114.224.060.375 alemtuzumab 123
D12.776.124.790.651.114.224.060.407 basiliximab 2
D12.776.124.790.651.114.224.060.438 bevacizumab 444
D12.776.124.790.651.114.224.060.469 brentuximab vedotin 38
D12.776.124.790.651.114.224.060.500 certolizumab pegol 47
D12.776.124.790.651.114.224.060.750 cetuximab 185
D12.776.124.790.651.114.224.060.766 daklizumab 6
D12.776.124.790.651.114.224.060.782 denosumab 150
D12.776.124.790.651.114.224.060.790 gemtuzumab 16
D12.776.124.790.651.114.224.060.794 inotuzumab ozogamicin 11
D12.776.124.790.651.114.224.060.798 ipilimumab 251
D12.776.124.790.651.114.224.060.813 natalizumab 156
D12.776.124.790.651.114.224.060.829 nivolumab 425
D12.776.124.790.651.114.224.060.844 omalizumab 111
D12.776.124.790.651.114.224.060.860 palivizumab 12
D12.776.124.790.651.114.224.060.864 panitumumab 57
D12.776.124.790.651.114.224.060.866 ramucirumab 1
D12.776.124.790.651.114.224.060.868 ranibizumab 60
D12.776.124.790.651.114.224.060.875 trastuzumab 267
D12.776.124.790.651.114.224.060.937 ustekinumab 120
D12.776.124.790.651.114.224.075 myší monoklonální protilátky 146
D12.776.124.790.651.114.224.306 kombinovaná protilátková terapie 7
D12.776.124.790.651.114.224.537 infliximab 340
D12.776.377 globuliny 68
D12.776.377.715 sérové globuliny 61
D12.776.377.715.548 imunoglobuliny 1 483
D12.776.377.715.548.114 protilátky 1 814
D12.776.377.715.548.114.224 monoklonální protilátky 4 611
D12.776.377.715.548.114.224.200 humanizované monoklonální protilátky 2 757
D12.776.377.715.548.114.224.200.125 abciximab 14
D12.776.377.715.548.114.224.200.250 adalimumab 346
D12.776.377.715.548.114.224.200.375 alemtuzumab 123
D12.776.377.715.548.114.224.200.407 basiliximab 2
D12.776.377.715.548.114.224.200.438 bevacizumab 444
D12.776.377.715.548.114.224.200.469 brentuximab vedotin 38
D12.776.377.715.548.114.224.200.500 certolizumab pegol 47
D12.776.377.715.548.114.224.200.750 cetuximab 185
D12.776.377.715.548.114.224.200.766 daklizumab 6
D12.776.377.715.548.114.224.200.782 denosumab 150
D12.776.377.715.548.114.224.200.790 gemtuzumab 16
D12.776.377.715.548.114.224.200.794 inotuzumab ozogamicin 11
D12.776.377.715.548.114.224.200.798 ipilimumab 251
D12.776.377.715.548.114.224.200.813 natalizumab 156
D12.776.377.715.548.114.224.200.829 nivolumab 425
D12.776.377.715.548.114.224.200.844 omalizumab 111
D12.776.377.715.548.114.224.200.860 palivizumab 12
D12.776.377.715.548.114.224.200.864 panitumumab 57
D12.776.377.715.548.114.224.200.866 ramucirumab 1
D12.776.377.715.548.114.224.200.868 ranibizumab 60
D12.776.377.715.548.114.224.200.875 trastuzumab 267
D12.776.377.715.548.114.224.200.937 ustekinumab 120
D12.776.377.715.548.114.224.284 myší monoklonální protilátky 146
D12.776.377.715.548.114.224.463 kombinovaná protilátková terapie 7
D12.776.377.715.548.114.224.642 infliximab 340